Organs of Tiruppur road accident victim declared brain dead, donated to save multiple lives at Tiruchi hospital
A team of doctors at Apollo Speciality Hospitals in Tiruchi, India, successfully harvested organs from a 45-year-old brain-dead road accident victim, saving the lives of several patients in need of transplants. The woman, a resident of Kannivadi village in Tiruppur district, was involved in a road accident on January 14 and was initially treated at Apollo Hospitals in Karur before being transferred to the Tiruchi facility. Despite receiving intensive care, she was declared brain dead by the medical team.
The woman’s family made the selfless decision to donate her organs, which were then retrieved through a series of coordinated surgical procedures. The harvested organs included her heart, liver, kidneys, and lungs. The liver and kidneys were transplanted into patients at Apollo Speciality Hospitals in Tiruchi, while the remaining organs were allocated to patients on the waiting list in accordance with the guidelines of the Tamil Nadu Transplant Authority (TRANSTAN).
The organ donation was carried out with the full support of the woman’s family, who were praised for their generosity and selflessness. The hospital officials and local authorities also played a key role in facilitating the donation process. The mortal remains of the organ donor were laid to rest with full honors, with the final rites conducted in the presence of officials from the District Collector of Tiruppur, including the Dharapuram Revenue Divisional Officer and Tahsildar Officer, as well as senior police officials and representatives from Apollo Speciality Hospitals.
This heartwarming story highlights the importance of organ donation and the impact it can have on saving lives. The selfless act of the woman’s family has given a new lease of life to several patients in need of transplants, and serves as an inspiration to others to consider organ donation. The successful transplantation of the organs is a testament to the expertise and dedication of the medical team at Apollo Speciality Hospitals, and the coordination and support of the local authorities and TRANSTAN.
US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue and margin driver for Indian drugmakers such as Dr Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Sun Pharma. However, with the patent expiry in January 2026, these companies will have to offload their remaining quotas, leading to a decline in sales.
Analysts expect a sector-wide decline in earnings before interest, taxes, depreciation, and amortization (Ebitda) margins by 150 basis points year-on-year, with companies such as Dr Reddy’s, Cipla, and Zydus Lifesciences likely to be affected. The decline in Revlimid sales will be a significant contributor to this margin pressure, with prices expected to erode sharply as players look to offload remaining quotas. Additionally, other factors such as increased generic price competition in the US market, higher research and development (R&D) expenses, and rising selling, general, and administrative (SG&A) costs will also weigh on margins.
Despite these challenges, analysts remain optimistic about the sector’s overall revenue growth, with expectations of 8-11% growth driven by steady domestic growth and traction in other markets. Domestic sales are projected to outpace the broader Indian pharmaceutical market’s 10.1% growth, with the chronic segment showing particular strength. Companies such as Lupin, Sun Pharma, and Cipla are expected to see growth driven by their innovative medicines portfolios and recent launches.
The US market, however, is expected to be a challenge, with overall US sales projected to decline by 4% quarter-on-quarter due to lower Revlimid sales. Excluding Revlimid, US generic sales are forecast to grow by 2% quarter-on-quarter, driven by volume expansion in existing products and the benefits from recent launches. Overall, while the loss of Revlimid patent exclusivity will be a significant challenge for Indian pharmaceutical companies, their domestic growth and innovative medicines portfolios are expected to provide some resilience and drive overall revenue growth.
A 14-year-old patient suffering from sickle cell disease undergoes hip replacement surgery at Apollo Hospital.
A 14-year-old girl from Nigeria, Grace Natasha Mwanasa, has undergone a successful total hip replacement surgery at Indraprastha Apollo Hospital in New Delhi. The surgery, led by renowned orthopaedic surgeon Dr. Yash Gulati, is one of the youngest cases of total hip arthroplasty in a patient with sickle cell disease. Grace was diagnosed with sickle cell disease in early childhood and had experienced recurring sickle cell crises, requiring multiple hospitalizations, ICU care, and blood transfusions.
In December 2025, Grace was admitted to Apollo Hospital with severe left hip pain, inability to walk, limping, and disturbed sleep due to constant pain. Evaluation revealed advanced avascular necrosis and complete destruction of the left femoral head, a known complication of sickle cell disease. Due to her severe pain, complete loss of hip movement, and significant functional disability, the medical team decided to proceed with total hip replacement.
The surgery required extensive preoperative planning, including an exchange blood transfusion to reduce HbS levels, which is a key component of sickle cell disease. The medical team also took precautions during anesthesia and surgery, including hydration, prevention of hypothermia, and meticulous bleeding control. The surgery was a success, and Grace is expected to recover and regain her mobility.
Dr. Gulati and his team’s expertise and careful planning were crucial in the success of the surgery. The case highlights the importance of timely and proper medical intervention in managing sickle cell disease and its complications. The surgery has given Grace a new lease on life, and she is expected to make a full recovery. The case also underscores the capabilities of Indian healthcare, with Indraprastha Apollo Hospital emerging as a hub for complex surgeries and treatments. The successful surgery has brought hope to patients suffering from sickle cell disease and other complex medical conditions, and has demonstrated the potential for effective treatment and management of these conditions with proper medical care.
Apollo Hospitals Managing Director denies rumors of a family feud, citing the demerger as a deliberate business strategy.
Apollo Hospitals Enterprise is undergoing a significant restructuring process, spinning off its pharmacy and digital health businesses into a separate entity called Apollo HealthCo. Managing Director Suneeta Reddy has clarified that this decision is driven by a desire to enhance shareholder value and is not related to family differences or changes in promoter dynamics. The restructuring is intended to create focused value for shareholders by allowing each business to operate with tailored strategies and metrics.
The hospital business and pharmacy-digital business have fundamental differences, including their nature, return profile, growth drivers, and workforce. The hospital business is focused on healthcare services, while the pharmacy-digital business is retail-focused. The spin-off will allow each business to operate independently and make decisions that are best for their respective industries.
Apollo HealthCo is projected to achieve 20% growth and is expected to be listed by FY27. The hospitals business is expected to grow at 18% over the next three years. The company is pivoting towards preventive healthcare, driven by the increasing burden of non-communicable diseases in India. Key health challenges, such as genetic predisposition to cardiac problems, rising cancer incidences, and India’s large diabetic population, are driving this strategic shift.
The company has ambitious expansion plans, including continued focus on metro cities, building a significant presence in tier-I cities, and exploring opportunities in tier-II cities. Apollo is also open to asset-light models and acquisitions, recognizing the significant healthcare infrastructure gap in India.
The company is investing in technology, including telemedicine and AI-powered clinical intelligence, to scale high-quality clinical offerings to larger populations. Looking ahead, Apollo is preparing to serve diverse demographic cohorts, from the growing geriatric population to millennials and Gen Z, each requiring tailored healthcare approaches encompassing preventive health, lifestyle interventions, and nutraceuticals. The restructuring and expansion plans are intended to position Apollo for long-term success and growth in the healthcare industry.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.